本页面由Tiger Trade Technology Pte. Ltd.提供服务

Sarepta Therapeutics

17.61
-0.1000-0.56%
盘后17.760.1500+0.85%16:08 EDT
成交量:216.74万
成交额:3,816.56万
市值:18.45亿
市盈率:-2.47
高:17.85
开:17.49
低:17.25
收:17.71
52周最高:76.26
52周最低:10.42
股本:1.05亿
流通股本:9,516.78万
量比:0.92
换手率:2.28%
股息:- -
股息率:- -
每股收益(TTM):-7.1300
每股收益(LYR):-7.1300
净资产收益率:-53.47%
总资产收益率:-11.24%
市净率:1.62
市盈率(LYR):-2.47

数据加载中...

公司资料

公司名字:
Sarepta Therapeutics
交易所:
NASDAQ
成立时间:
1980
员工人数:
835
公司地址:
215 First Street,Suite 415,Cambridge,Massachusetts,United States
邮编:
02142
电话:
传真:
- -
简介:
Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业化阶段的生物制药公司,专注于发现和开发独特的RNA靶向疗法、基因疗法和其他遗传治疗方式,用于治疗罕见病。它已开发出多种获批的杜氏肌营养不良症治疗药物,并正在推进针对其他神经肌肉和骨骼疾病的候选药物。

董事

名称
职位
Douglas Ingram
Director,Chief Executive Officer
Claude Nicaise
Independent Director
Deirdre P. Connelly
Independent Director
Hans Wigzell
Independent Director
Kathryn Jean Boor
Independent Director
M. Kathleen Behrens
Chairwoman of the Board
Michael A. Chambers
Independent Director
Richard J. Barry
Independent Director
Stephen L. Mayo
Independent Director

股东

名称
职位
Douglas Ingram
Director,Chief Executive Officer
Ian Estepan
President and Chief Operating Officer
Ryan Wong
Executive Vice President, Chief Financial Officer,Principal Accounting Officer
Cristin Rothfuss
Executive Vice President, Chief General Counsel and Corporate Secretary
Louise Rodino Klapac
President, Research and Development and Technical Operations